Bioceltix Company Description

Bioceltix S.A. engages in the development of veterinary biologics based on mesenchymal stem cells.

The company’s products include BCX-CM-J, a stem-cell based medicinal drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, an allogeneic stem cell-based medicinal product for the treatment of atopic dermatitis in dogs; and BCX-EM, an allogeneic stem cell-based medicinal product for the treatment of osteoarthritis in horses.

It also develops BCX-CM-Sec, a research project aimed at developing a cell-free biological drug to treat atopic dermatitis in dogs.

The company was founded in 2016 and is headquartered in Wroclaw, Poland.

Bioceltix S.A.

Country	Poland
Founded	2016
Industry	Biotechnology
Sector	Healthcare
Employees	46
CEO	Lukasz Bzdzion

Contact Details

Address: bud. III Wroclaw, 51-317 Poland
Phone	48 534 37 38 08
Website	bioceltix.com

Stock Details

Ticker Symbol	BCX
Exchange	Warsaw Stock Exchange
Fiscal Year	January - December
Reporting Currency	PLN
ISIN Number	PLBCLTX00019
SIC Code	2836

Key Executives

Name	Position
Lukasz Bzdzion	Chief Executive Officer and President of the Management Board
Dr. Pawel Wielgus Eng., Ph.D.	Member of the Management Board
Andrij Wlach	Chief Financial Officer
Grzegorz Ostropolski	Chief Operating Officer
Lahoud Touma	Director of Technology
Jakub Wacek	Legal Counsel and General Counsel
Dr. Patryk Reniewicz Ph.D.	Head of Research & Development and Leader of the In Vitro Diagnostics Development Team
Agnieszka Kielczykowska	Head of Procurement and Supply
Anna Olko-Chudy	Head of the Management Office and Tissue Coordinator
Katarzyna Wroblewska	Head of Quality Assurance